Altiparmak M R, Pamuk O N, Pamuk G E, Hamuryudan V, Ataman R, Serdengecti K
Department of Nephrology, Cerrahpasa Medical School, University of Istanbul, Turkey.
Clin Exp Rheumatol. 2002 Jul-Aug;20(4 Suppl 26):S13-6.
Colchicine has been in use for therapeutic purposes for many years. It can, however, cause subacute onset muscle and peripheral nerve toxicity in patients with chronic renal failure. In this report we describe 6 patients who developed neuromyopathy after the administration of colchicine. All patients presented with proximal muscle weakness, elevated serum creatine kinase (CK) levels, and neuropathy and/or myopathy on electromyography (EMG). The diagnosis of colchicine toxicity was confirmed in all cases by the normalization of CK levels and EMG after discontinuation of the drug. Toxicity developed in 4 renal failure patients on therapeutic doses of the drug, while one patient took a massive dose for suicidal reasons, and the other was on high-dose therapy. Patients using colchicine--especially those with renal failure--should be warned about the side effects of the drug and physicians should be careful in the administration of the drug.
秋水仙碱已用于治疗目的多年。然而,它可导致慢性肾衰竭患者出现亚急性起病的肌肉和周围神经毒性。在本报告中,我们描述了6例在服用秋水仙碱后发生神经肌肉病变的患者。所有患者均表现为近端肌无力、血清肌酸激酶(CK)水平升高,且肌电图(EMG)显示有神经病变和/或肌病。所有病例在停药后CK水平和EMG恢复正常,从而确诊为秋水仙碱中毒。4例肾衰竭患者在接受治疗剂量的该药时出现毒性反应,1例患者因自杀原因服用了大剂量药物,另1例患者接受高剂量治疗。使用秋水仙碱的患者——尤其是肾衰竭患者——应被告知该药的副作用,医生在给药时应谨慎。